Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Comparative treatment planning of photon, proton and carbon ion radiotherapy for sphenoid wing meningiomas.

Created on 01 Jul 2026

Authors

Sophie Rauh, Maximilian Y Deng, Inga Jessen, Lisa Seidel, Line Hoeltgen, Semi Harrabi, Filipa Baltazar, Thomas Haberer, Andrea Mairani, Klaus Herfarth, Jürgen Debus, Thomas Tessonnier, Laila König

Published in

Physics and imaging in radiation oncology. Volume 39. Pages 101018. Epub Jun 13, 2026.

Abstract

Sphenoid wing meningiomas (SWMs) are located adjacent to critical organs of interest (OOIs) and present challenges for surgery and radiotherapy. Given the favorable overall survival in meningioma patients, preserving quality of life is important. Dose reductions within OOIs may lower adverse events. This study aimed to evaluate potential advantages of particle therapy regarding dose distribution and side effects for SWMs.
Nine patients (eight females, one male; median age at radiotherapy: 55 years) with SWM received proton radiotherapy (PRT, 54 Gy (RBE), 1.8 Gy (RBE) per fraction). Comparative treatment plans were generated for volumetric modulated arc therapy (VMAT, 54 Gy, 1.8 Gy per fraction) and carbon ion radiotherapy (CIRT, 42 Gy (RBE), 3 Gy (RBE) per fraction). Target volumes and OOI dose guidance were maintained. OOI dose-volume parameters, normal tissue complication probabilities (NTCP), and risk ratios of radiation-induced secondary central nervous system (CNS) malignancies were assessed.
Compared to VMAT, mean relative brain doses were reduced by -41.5% with PRT, and - 63.8% with CIRT. Particle therapy achieved significant dose sparing of bilateral hippocampi and lenses, and the ipsilateral inner ear. NTCPs indicated lower risks of ipsilateral hearing loss and cataract with particle therapy. The mean estimated risk of radiation-induced secondary malignancies was 1.7 for photons over protons, and 2.7 for photons over carbon ions.
For SWMs, particle therapy demonstrated reduced dose exposure to several OOIs, and may lower the risk of side effects compared with VMAT.

PMID:
42382598
Bibliographic data and abstract were imported from PubMed on 01 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement